期刊文献+

低分子肝素钠与低分子肝素钙治疗不稳定型心绞痛的疗效比较 被引量:6

Comparison of therapeutic efficacy of low-molecular heparin sodium (Futos) and low-molecular heparin calcium (Fraxiparine) for unstable angina pectoris
下载PDF
导出
摘要 目的:对比观察国产低分子肝素钠(活多史)与进口低分子肝素钙(速碧林)对不稳定型心绞痛(UAP)的疗效及副作用.方法:将60例UAP患者随机分为活多史组与速碧林组(各30例),在常规治疗的基础上分别予以活多史0.4mL(4250U)和速碧林0.4mL(4100U)腹壁皮下注射,2次/d共7d.观察临床显效率、总有效率、急性心肌梗死率、出血事件发生率等.结果:两组对心绞痛的临床显效率、总有效率、急性心肌梗死率、出血事件发生率分别为66.7%(20/30)vs70.0%(21/30),90.0%(27/30)vs93.3%(28/30),3.3%(1/30)vs3.3(1/30),13.3(4/30)vs10.0%(3/30),无统计学差异.结论:国产低分子肝素钠(活多史)是治疗UAP安全、有效的药物. AIM: To observe the efficacy and side effects of lowmolecular heparin sodium( Futos ) for unstable angina pectoris and compare with that of low-molecular heparin calcium ( Fraxiparine). METHODS: Sixty patients with unstable angina pectoris were randomly divided into Futos group and Fraxiparine group ( n =30, respectively). In addition to general treatments, they were given abdominal subcutaneous injection of Futos 0.4mL(4250 U) or Fraxiparine 0.4 mL(4100 U), two times per day for 7 d. The marked efficiency rates, total efficiency rates, acute myocardial infarction rates and bleeding event rates were observed. RESULTS: In Futos group and Fraxiparine group, the marked efficiency rates, total efficiency rates, acute myocardial infarction rates and bleeding event rates were respectively 66.7% (20/30) vs 70.0% (21/30), 90.0% (27/30) vs 93.3% (28/30), 3.3% (1/30) vs3.3%(1/30), 13.3% (4/30) vs 10.0%(3/30), and there was no statistically significant differences. CONCLUSION: Homemade low-molecular heparin sodium (Futos) is a safe and effective drug for the patients with unstable angina pectoris.
出处 《第四军医大学学报》 北大核心 2008年第4期320-321,共2页 Journal of the Fourth Military Medical University
关键词 低分子肝素钠 心绞痛 不稳定型 low-molecular heparin sodium angina, unstable
  • 相关文献

参考文献4

  • 1Shafiq N, Malhotra S, Pandhi P, et al. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparinsenoxaparin, nadroparin and dalteparin. The ESCAPe-END study [J]. Pharnaeology, 2006,78(3) :136-143. 被引量:1
  • 2Ageno W, Turpie AG. Low molecular weight heparins in the treatment of unstable angina[ J ]. Minerva Cardioangiol, 2002,50 ( 6 ) : 643 -651. 被引量:1
  • 3郭晓华,柴小奇,王敬,吴先军.长疗程低分子量肝素治疗急性冠脉综合征68例[J].心脏杂志,2006,18(5):602-603. 被引量:4
  • 4LaPointe NM, Chen AY, Alexander KP, et al. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes[ J]. Arch Intern Med, 2007,167(14) :1539 - 1544. 被引量:1

二级参考文献3

共引文献3

同被引文献31

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部